The Cincinnati Children's confined culture system represents a preclinical experimental advance rather than an RCT, relying on iPSC-derived spheroids from an unspecified donor pool and rodent xenotransplants with genetically modified models to minimize rejection. While the team reports organoids reaching functional maturity in 14 days versus 28 previously—with self-organized enteric neurons and up to 8 cm of engrafted tissue—the study provides no details on sample sizes for human iPSC lines or statistical powering, limiting generalizability. Original coverage overlooks connections to the gut-brain axis: these neuromuscular organoids could enable superior in vitro models for disorders like IBS or Parkinson's, where enteric neuropathy plays a role, building on prior work such as the 2017 Nature paper by Workman et al. on hPSC-derived enteric neurons and the 2022 Cell Stem Cell study by Eicher et al. scaling GI organoids. Conflicts of interest at Cincinnati Children's CuSTOM, focused on commercialization, warrant scrutiny as the platform moves toward personalized therapies. This engineering approach highlights how physical confinement exploits intrinsic self-organization, a pattern missed in earlier manual methods, yet scalability to human trials remains untested.